The future of breast cancer screening and risk-reducing strategies is being shaped by artificial intelligence (AI), according to a recent review article.

Cancer patient and Illinois State University graduate Moji Kalantari is developing an app aimed at creating communities among ...

B reast cancer is not a single disease but multiple ones, each carrying varying degrees of risk for endangering women’s ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

DCIS, known as stage 0 breast cancer, affect the cells lining the milk ducts but has not spread outside the breast.

The rates of late-stage breast cancer at diagnosis have risen among women in all racial and ethnic groups, but Black women ...

Kisqali has shown to improve survival in advanced breast cancer; Ibrance has not. While early data had indicated a medicine ...

a population that represents 10% of breast cancer patients. Although not a game-changer for Pfizer, the data could could help ...

Patients included in the trial had HR+/HER2– metastatic breast cancer, were 18 years or older, and started index treatment ...

Some early breast cancer patients can safely avoid specific surgeries, according to two studies exploring ways to lessen treatment burdens. One new study, published in the New England Journal of ...

Younger patients are more likely to have genetic risk factors for breast cancer, according to the Breast Cancer Research ...